FDA Final Rules Align Clinical Research Regulations With Expanded Nonclinical Data
核心洞察
The FDA issued a direct final rule amending regulations for human drugs and biologics to replace animal testing references with broader nonclinical testing terminology.
The change reflects evolving scientific methods in nonclinical testing and does not impose new requirements on sponsors or manufacturers.
The rule aligns FDA regulations with expanded nonclinical testing approaches as the agency updates its regulatory language.
The FDA has issued a direct final rule amending regulations governing human drugs and biologics, replacing references to animal testing with broader nonclinical testing terminology. The agency said the change reflects evolving scientific methods without imposing new requirements.
The rule aligns FDA regulations with expanded nonclinical testing approaches, updating the language used across the affected regulations.